Capital Wealth Planning LLC Buys 20,328 Shares of Astrazeneca Plc $AZN

Capital Wealth Planning LLC lifted its stake in shares of Astrazeneca Plc (NYSE:AZN) by 24.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 104,642 shares of the company’s stock after acquiring an additional 20,328 shares during the period. Capital Wealth Planning LLC’s holdings in Astrazeneca were worth $8,028,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rakuten Investment Management Inc. acquired a new stake in shares of Astrazeneca in the 3rd quarter valued at about $31,000. FSA Wealth Management LLC grew its stake in shares of Astrazeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after buying an additional 376 shares during the period. VSM Wealth Advisory LLC bought a new stake in Astrazeneca in the 2nd quarter valued at about $33,000. E Fund Management Hong Kong Co. Ltd. raised its stake in Astrazeneca by 144.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after buying an additional 275 shares during the period. Finally, Abound Wealth Management raised its stake in Astrazeneca by 1,767.9% during the 3rd quarter. Abound Wealth Management now owns 523 shares of the company’s stock worth $40,000 after buying an additional 495 shares during the period. 20.35% of the stock is owned by institutional investors.

Astrazeneca Price Performance

Shares of AZN opened at $190.20 on Friday. The company has a market cap of $294.98 billion, a price-to-earnings ratio of 21.01, a P/E/G ratio of 1.45 and a beta of 0.32. Astrazeneca Plc has a 52 week low of $122.48 and a 52 week high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be issued a dividend of $1.595 per share. The ex-dividend date is Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio is 66.26%.

Analysts Set New Price Targets

AZN has been the subject of a number of research reports. Barclays reissued an “overweight” rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Wall Street Zen cut Astrazeneca from a “buy” rating to a “hold” rating in a report on Thursday. HSBC reissued a “buy” rating and issued a $108.00 price target on shares of Astrazeneca in a research report on Wednesday, December 10th. Citigroup initiated coverage on shares of Astrazeneca in a research note on Tuesday, January 27th. They set a “buy” rating for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 price objective on shares of Astrazeneca in a research note on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.